CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 21 enrolled
Drug / intervention
oral capsule of Q-122drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04080297
NCT04080297Phase 1Completed
CompareCT.gov

A Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects With Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen

Que Oncology·interventional·Posted Sep 6, 2019·Updated Feb 28, 2020

In Brief

A Phase 1 clinical trial evaluating oral capsule of Q-122 for Vasomotor Symptoms (VMS). Completed, enrolled 21 participants.

Detailed Summary

Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasomotor Symptoms (VMS)
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartJan 10, 2014
Primary CompletionJul 28, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.8 years ago

Interventions

oral capsule of Q-122drug